PHARMACYTE BIOTECH INC (PMCB) Stock Price, Quote, News and Overview
NASDAQ:PMCB - Nasdaq - US71715X2036 - Common Stock - Currency: USD
PMCB Quote, Performance and Key Statistics
NASDAQ:PMCB (7/3/2025, 8:00:46 PM)
1.11
-0.03 (-2.63%)
The current stock price of PMCB is 1.11 USD. In the past month the price increased by 1.83%. In the past year, price decreased by -46.89%.
PMCB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 334.34B | ||
| AMGN | AMGEN INC | 14.37 | 160.37B | ||
| GILD | GILEAD SCIENCES INC | 14.44 | 139.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.35 | 59.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 43.28B | ||
| ARGX | ARGENX SE - ADR | 94.52 | 33.18B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.26 | 26.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.44B | ||
| NTRA | NATERA INC | N/A | 22.09B | ||
| BIIB | BIOGEN INC | 8.4 | 19.47B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.23B |
Related stock screener links
About PMCB
Company Profile
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The company is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. The company is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. The company is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The company is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Company Info
PHARMACYTE BIOTECH INC
3960 Howard Hughes Parkway, Suite 500
Las Vegas NEVADA US
CEO: Kenneth L. Waggoner
Employees: 2
Phone: 19175952850
PHARMACYTE BIOTECH INC / PMCB FAQ
What is the stock price of PHARMACYTE BIOTECH INC today?
The current stock price of PMCB is 1.11 USD. The price decreased by -2.63% in the last trading session.
What is the ticker symbol for PHARMACYTE BIOTECH INC stock?
The exchange symbol of PHARMACYTE BIOTECH INC is PMCB and it is listed on the Nasdaq exchange.
On which exchange is PMCB stock listed?
PMCB stock is listed on the Nasdaq exchange.
What is PHARMACYTE BIOTECH INC worth?
PHARMACYTE BIOTECH INC (PMCB) has a market capitalization of 7.61M USD. This makes PMCB a Nano Cap stock.
How many employees does PHARMACYTE BIOTECH INC have?
PHARMACYTE BIOTECH INC (PMCB) currently has 2 employees.
What are the support and resistance levels for PHARMACYTE BIOTECH INC (PMCB) stock?
PHARMACYTE BIOTECH INC (PMCB) has a support level at 1.01 and a resistance level at 1.14. Check the full technical report for a detailed analysis of PMCB support and resistance levels.
Should I buy PHARMACYTE BIOTECH INC (PMCB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PMCB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PMCB, evaluating the profitability, health, valuation and growth aspects
- PHARMACYTE BIOTECH INC (PMCB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PHARMACYTE BIOTECH INC (PMCB) Sales and EPS estimates to see what analysts future expectations are.
- PHARMACYTE BIOTECH INC (PMCB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PHARMACYTE BIOTECH INC (PMCB) Insider and Institutional Ownership to learn about the owners and their transactions.
- PHARMACYTE BIOTECH INC (PMCB) Stock Chart to make your own analysis
- PHARMACYTE BIOTECH INC (PMCB) Latest news and press-releases to stay up to date.
Does PHARMACYTE BIOTECH INC (PMCB) stock pay dividends?
PMCB does not pay a dividend.
When does PHARMACYTE BIOTECH INC (PMCB) report earnings?
PHARMACYTE BIOTECH INC (PMCB) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of PHARMACYTE BIOTECH INC (PMCB)?
The PE ratio for PHARMACYTE BIOTECH INC (PMCB) is 1.01. This is based on the reported non-GAAP earnings per share of 1.1 and the current share price of 1.11 USD. Check the full fundamental report for a full analysis of the valuation metrics for PMCB.
What is the Short Interest ratio of PHARMACYTE BIOTECH INC (PMCB) stock?
The outstanding short interest for PHARMACYTE BIOTECH INC (PMCB) is 0.35% of its float. Check the ownership tab for more information on the PMCB short interest.
PMCB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PMCB. When comparing the yearly performance of all stocks, PMCB is a bad performer in the overall market: 93.44% of all stocks are doing better.
PMCB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PMCB. While PMCB has a great health rating, there are worries on its profitability.
PMCB Financial Highlights
Over the last trailing twelve months PMCB reported a non-GAAP Earnings per Share(EPS) of 1.1. The EPS increased by 170.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 19.7% | ||
| ROE | 21.45% | ||
| Debt/Equity | 0 |
PMCB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to PMCB. The Buy consensus is the average rating of analysts ratings from 6 analysts.